INTRODUCTION
The erythrocytes (E)l of patients with paroxysmal nocturnal hemoglobinuria (PNH E) may be classified into three types according to their susceptibility to the lytic Received for publication 24 July 1981 and in revised form 7 October 1981. 1 Abbreviations used in this paper: C3NeF, C3 nephritic factor; E, erythrocytes; EC3b, erythrocytes bearing large numbers of C3b molecules after activation of fluid-phase C3 by erythrocytes bearing the stabilized convertase; ECMb, erythrocytes bearing small numbers of C3b molecules after activation of fluid-phase C3 by trypsin; EC3bBbC3NeF, erythrocytes bearing the alternative pathway convertase stabilized by C3 nephritic factor; '25j-anti-C3, radiolabeled monoclonal antibody to C3; 125I-B, radiolabeled factor B; '31I-C3NeF, radiolabeled CS nephritic factor; GVB, veronalbuffered saline containing 0.1% gelatin; GVB+, GVB containing 5 mM magnesium. action of complement: PNH I cells, which appear to be normal or nearly normal in their susceptibility; PNH II cells, which are moderately susceptible to lysis, requiring one-third to one-fifth as much complement for lysis equal to that of normal E; and PNH III cells, which are markedly susceptible to lysis, requiring 1/ 15 to 1/25 as much complement for lysis as normal cells (1, 2) . In previous studies (3) (4) (5) (6) , it has been demonstrated that both PNH II and PNH III cells bind much more C3b per cell than do normal cells when the complement in whole serum is activated either by the classical or the alternative pathway. The increased binding of C3b to PNH II cells appears to account entirely for the increased susceptibility of these cells to lysis, inasmuch as they show the same sensitivity to the lytic effects of the C5b-9 complex as do normal E (3, 6) . The greater susceptibility to lysis of PNH III cells compared with PNH II cells appears to reside in a second defect that results in greater efficiency of the C5b-9 lytic complex.
The binding of C3b to E plays a pivotal role in the lysis of E by complement by mediating the activation of CS by the C4b2a complex. More importantly, cellbound C3b creates a nidus for the formation of the alternative pathway convertase complexes that activate CS and C5, markedly amplifying the formation of terminal complexes. In addition, cell-bound C3b serves to concentrate the fixation of the C5b6 complex to the cell, thereby greatly potentiating complementmediated hemolysis (7) .
The interactions of the components of the alternative pathway of complement with the microenvironment of surfaces to which they affix are complex (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) , and the increase in the amount of C3b bound to the surface of PNH E may be the result of increased efficiency of binding of nascent C3b, enhanced activation of fluid-phase C3, or decreased degradation of bound C3b.
We have investigated the interactions of the alternative pathway convertase components with the membrane of the abnormal PNH E in an attempt to determine the reasons for the greater fixation of C3 to that cell, and thereby, to gain insight into the biochemistry of the membrane defect that accounts for this phenomenon. Our studies indicate that the abnormal PNH E does not bind nascent C3b more efficiently and that the greater fixation of C3b to PNH E is not the result of a difference in the intrinsic or extrinsic stability of the convertase when bound to PNH or normal E. When C3 is activated by the C3 nephritic factor-stabilized cell-bound alternative pathway convertase, C3bBbC3NeF, more C3b is bound to PNH E than normal E because more fluid-phase C3 is converted to nascent C3b by the stabilized convertase when fixed to PNH E. This greater conversion is due to the enhanced enzymatic activity of the convertase on PNH E. We believe this to be the first instance in which the enzymatic activity of a complement convertase has been demonstrated to be enhanced because of interactions with an abnormal surface.
METHODS
Buffers. Veronal-buffered saline, pH 7.5, veronal-buffered saline containing 0.1% gelatin (GVB), GVB containing 5 mM magnesium (GVB+), and Alsever's solution were prepared as outlined (19) .
Human E. E from normal donors (normal E) and patients with PNH (PNH E) were prepared and stored as previously described (4) . The PNH cells used for these experiments had 85% or greater markedly complement-sensitive (PNH III) erythrocytes. Complement components and antibody. C3 was purified to homogeneity as assessed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (20) according to the method of Lambris et al. (21) as modified from the method of Tack and Prahl (22) . Factor B was isolated by the following modification of the procedure of Gotze and Muller-Eberhard (23) . After the pseudoglobulins were sequentially chromatographed with DEAE-Sephacel (Pharmacia Fine Chemicals, Div. of Pharmacia Inc., Piscataway, N. J.) and Bio-Rex 70 (Bio-Rad Laboratories, Richmond, Calif.) as described, the factor B-containing pool was fractionated on Sephadex G-200 (Pharmacia Fine Chemicals). The final product revealed two bands in close proximity on sodium dodecyl sulfate polyacrylamide gel electrophoresis as described by Nicholson et al. (24) . Functionally purified factor D was isolated by gel filtration of normal human serum on Sephadex G-75 (Pharmacia Fine Chemicals) as described by Lambris et al. (21) . Partially purified C3 nephritic factor (C3NeF) was prepared from the plasma of a patient with partial lipodystrophy (kindly provided by Dr. W. Ray Gammon, University of North Carolina, Chapel Hill) by the method of Schreiber et al. (25) To quantitate the number of molecules of C3b bound per cell, 1 X 107 erythrocytes bearing large numbers of C3b molecules were incubated (for 30 min at 37°C) with 30 Ml of '251-anti-C3 (1.1 ,ug) and 20 Ml GVB+. The cells were washed two times in 4 ml of GVB. After the suspension had been transferred to another tube, the cells were once again washed, and the radioactivity of the pellet was determined. Normal and PNH E were included as controls for nonspecific binding of '25I-anti-C3, and this value was subtracted to define the specific binding used to calculate the cellbound C3b.
Preparation of PNH E and normal E bearing small numbers of C3b molecules. By a modification of the method of Pangburn and Miuller-Eberhard (15) , erythrocytes bearing small numbers of C3b molecules (C3b,) were prepared. Normal and PNH E were washed three times in GVB+ and suspended at a concentration of 1 X 109 cells/ml in the same buffer. 1 X 109 cells were incubated for 5 min at 37°C with 10 ul of C3 (1 mg) and 100 Ml of GVB+. 10 Ml (10 Mg) of trypsin (Sigma Chemical Co.) was added, and the incubation was continued for 3 min at 37°C. The reaction was stopped by the addition of 4 ml (200 MAg/ml GVB+) of trypsin inhibitor (Sigma Chemical Co.). The cells were washed three times in trypsin inhibitor and once in GVB+ and restored to 1 X 109/ml GVB+. The amount of C3b bound was determined with 251I-anti-C3 as described above. In the experiments indicated, the proportion of C3 and trypsin were increased to allow more C3b to be bound to normal E. To determine nonspecific binding of C3b, 10 ul of C3 (1 mg) was incubated with 10 Ml of trypsin (1 mg/ml), and after 3 min at 37°C, 30 Mul of trypsin inhibitor (1 mg/ml) was added. The reaction mixture was then incubated with 1 X 109 normal or PNH E and 70 Ml of GVB+ for 3 min at 37°C. The cells were washed three times with trypsin inhibitor (200 g/ ml in GVB+) and once in GVB+ and restored to 1 X 109/ml. The C3b bound to each cell type was determined with 1251_ anti-C3 as described above, and this value was subtracted to define specific binding of C3b to each cell type after trypsin activation of C3.
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Establishment of erythrocytes bearing a stabilized alternative pathway convertase (EC3bBbC3NeF). 1 X 10g normal and PNH EC3b, were incubated with 25 Ml of factor B (50 Mg), 20 MAl of functionally purified factor D, and 50 Ml of C3NeF (155 gg) for 10 min at 37°C. The cells were then washed with 4 ml of GVB+, resuspended to 1 X 109/ml in GVB+, and used immediately. To quantitate the stabilized alternative pathway convertase sites, radiolabeled factor B and/or radiolabeled C3NeF were employed as markers. Normal and PNH E were included as controls for nonspecific binding of radiolabeled factor B and C3NeF, and this value was subtracted to define the specific binding of each protein.
Determination of stabilized cell-bound alternative pathway convertase activity. 1 X 108 normal and PNH EC3BbC3NeF were incubated for various periods of time with 100 Ml of C3 (200 Mg) and GVB+. The supernatant fluid was recovered, and fluid-phase CS conversion to C3b was determined by crossed immunoelectrophoresis (27) with antiserum monospecific for C3 (Atlantic Antibody, Scarborough, Maine). The amount of CS bound to normal and PNH E after C3 conversion by EC3bBbC3NeF was determined with '251-anti-C3 as described above. The amount of C3b bound to each cell type after the trypsinization step was subtracted to give the net C3b bound.
Preparation of PNH E and normal E bearing large numbers of C3b molecules. By a modification of the method of Pangburn and Muller-Eberhard (15) 
RESULTS
Binding of nascent C3b to PNH and normal E. To test whether nascent C3b binds more readily to PNH E than to normal E, fluid-phase C3 was activated by trypsin in the presence of normal and PNH E. When equal numbers of PNH and normal E were incubated with equal amounts of C3 and trypsin, the number of molecules of C3b bound per cell was the same for both cell types (Table I) .
The efficiency of binding of nascent C3b to normal and PNH E was further determined by measuring the binding of C3 converted by cell-bound stabilized alternative pathway convertases. Equivalent numbers of PNH and normal EC3bBbC3NeF were incubated with purified C3, and at intervals, the amount of C3 converted to C3b and the amount of C3b bound were determined. The proportion of C3 converted and then bound was the same for normal and PNH E (Fig. 1) .
Binding of 125I-B to EC3b. If the amount of C3b bound to PNH and normal E were the same, greater Table III were incubated with fluid-phase C3, a similar greater conversion of C3 was found ,--i I I l (Table IV) (Table IV) .
Decay of 125I-B from EC3bBbC3NeF. Increased conversion of C3 to C3b by PNH E bearing the stabilized alternative pathway convertase could be re--300 lated to a greater intrinsic stability of the stabilized o / convertase when present upon PNH E compared with normal E. Therefore, the decay kinetics of '251-B from PNH and normal E bearing the stabilized convertase '-' 200 were assessed (Fig. 5) . The difference between the two curves is small, indicating that a difference in the intrinsic stability of the convertase does not account for * t the increased conversion of C3 to C3b by PNH EC3bBbC3NeF.
100-
Agglutination of EC3bBbC3NeF. C3NeF is an antibody and is capable of agglutinating EC3bBb. PNH EC3bBbC3NeF agglutinated to a greater extent / _,__---~~~~~~~~~~than normal EC3bBbC3NeF when the number of stabilized convertase sites was equivalent (Table V) . that PNH E bind more C3b than do normal E when complement in serum is activated by either the clasmolecules bound per factor B bound is also somewhat sical or the alternative pathway. The present investigreater for PNH cells (Table III) . The ratio of "'lI-gations, in which purified components of the alterC3NeF molecules bound: 125I-B bound, determined in native pathway of complement were employed, have three separate experiments, was 0.496±0.063 for PNH confirmed the greater binding of C3b to PNH E when 342 C. J. Parker, P. J. Baker, and W. F. Rosse Determined by binding of "3'I-C3NeF. § Determined by crossed immunoelectrophoresis.
CS is activated by this pathway. This increased fixation of C3b was found to be due to an increase in the enzymatic activity of the alternative pathway convertase when sited upon the membrane of the PNH E. Other systems in which there is a relatively greater fixation of C3b to a particular surface have been described (8, (12) (13) (14) (15) (16) (17) . This greater binding could be attributed to difference in the biochemical composition of that surface that either favored binding of nascent C3b (8) (9) (10) or modified interactions of surface-bound C3b with the endogeneous control proteins (12) (13) (14) (15) (16) (17) . The latter, termed activator surfaces, favor the binding Neither of these known causes of excessive C3b binding pertain to PNH E. The same proportion of activated C3 is bound by normal and PNH cells (Table  I and Fig. 1) , showing that the PNH membrane does not more efficiently bind activated C3b. The increased conversion and fixation of C3 by PNH E bearing the alternative pathway convertase occurred in the absence of the control proteins, and further, the convertase complexes were stabilized with C3NeF, which renders them resistant to extrinsic decay by endogenous control proteins when they are present. However, it is possible that the endogenous control proteins may, in fact, interact aberrantly with elements of the alternative pathway convertase when present on PNH E in such a way as to contribute to the greater fixation of C3b to PNH E observed in whole-serum systems. For this reason, we are currently investigating the interactions of #31H and C3bINA with the alternative pathway convertase on PNH and normal E.
In the absence of the endogenous control proteins, the duration of activity of the alternative pathway (30, 31) . The number of C3b receptor sites on PNH and normal E appears to be the same.2 C3NeF prolongs the activity of the alternative pathway convertase by specifically binding to neoantigens exposed upon the formation of the convertase complex (32, 33) . This antibody retards the intrinsic decay of the catalytic Bb subunit from the convertase complex. Using 125I-B, we found no significant difference in the rate of decay of Bb from the stabilized convertase complex (EC3bBbC3NeF) when bound to PNH or normal E (Fig. 5) . Thus, in these experiments in which C3NeF was used to stabilize the cell-bound alternative pathway convertase, the increased conversion and concomitant increase in C3b bound by PNH E cannot be attributed to a difference in the intrinsic stability of the convertase when present upon PNH E compared with normal E.
The greater activation of C3 by convertase complexes appears to be due to a markedly greater enzyme activity of the convertase when it is fixed to PNH E. Each C3NeF-stabilized convertase complex fixed to PNH E converts four to five times more fluid-phase C3 to C3b than one fixed to normal E (Table IV and Fig. 4A ). This appears to be the first instance in which the kinetics of an enzyme of the complement system have been altered because of fixation of the enzyme complex to an abnormal surface. Detailed studies of the enzyme kinetics of the convertase when bound to normal and PNH E are underway to elucidate the nature of the difference in the enzyme-substrate interactions.
There are precedents to suggest that the biochemical properties of a membrane can influence the activity of membrane-associated enzymes (34) . This phenomenon may explain why PNH E lack acetylcholinesterase activity (35, 36) , inasmuch as the enzyme molecule is said to be present but its activity diminished (37, 38) due to changes in enzyme kinetics imposed by an abnormality of the lipid environment of the PNH membrane (38) . It is possible that the kinetics of the membrane-associated enzyme examined in the present study (the stabilized C3 convertase of the alternative pathway) may also be influenced by the lipid environment of the PNH E membrane.
Interactions between C3b and/or C3bB and the abnormal PNH E membrane may result in a spatial orientation of the C3b molecule or the C3bB complex that differs from that on normal E membrane. Although the difference in the ratio of '3'1-C3NeF:'25I-B binding to PNH E was not significantly different from that of normal E (P = 0.2), in general, higher numbers of C3NeF molecules were bound to PNH E. This suggests that the abnormal PNH E membrane may alter interactions between factor D and C3bB and/or between C3NeF and cell-bound C3bBb in such a way as to favor the formation of the stabilized alternative pathway convertase. The greater agglutination of PNH EC3bBbC3NeF (Table V) for a given amount of bound C3NeF suggests that the conformation of the alternative pathway convertase when bound to PNH E is aberrant. The cross-linking of cells by C3NeF reacting with C3 convertases may occur more readily on PNH E and reflect a difference in the accessibility of the surface-bound convertase to the antibody, and, perhaps, of the catalytic site for its substrate, C3.
The present investigations have been concerned with the C3 convertase complex of the alternative pathway. Activation of the classical pathway in the presence of whole serum (and hence of the components of the alternative pathway) also results in the fixation of more C3 to PNH E (3) (4) (5) (6) . In previous studies, we have shown that the formation of the convertase of the classical pathway (C4b2a) occurs equally on normal and PNH E, that the rate of degradation of that complex is the same (39) , and that the amount of a specific protein in the membrane that facilitates that degradation is the same on the two types of cells (40) . We are currently investigating the reactions of the C4b2a complex to determine whether the enzymatic activity of this complex likewise is increased when it is attached to the PNH E and the role activation of the alternative pathway by the classical pathway plays in the increased binding of C3 to PNH E when complement is activated by antibody.
The three known abnormalities of the PNH E membrane (increased activity of the alternative pathway convertase, decreased activity of acetylcholinesterase, and increased efficiency of the C5b-9 complex) could all be plausibly explained as the result of an abnormality or abnormalities in the lipids of the membrane. However, no consistent abnormalities in lipid composition of the PNH E membrane have been demonstrated (41 
